Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925104 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
A Phase 1 study of cMET Dysegulation Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 17
- Study locations
NCT02925104: Completed Phase 1 study of cMET Dysegulation Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
NCT02925104 is a Phase 1 study of cMET Dysegulation Advanced Solid Tumors that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 17 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02925104, a Phase 1 study of cMET Dysegulation Advanced Solid Tumors, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 17
- Study locations
Study Summary
Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food in patients with cMET dysregulated advanced solid tumors.
Conditions Studied
Interventions
- DRUG INC280
Study Locations (17)
Other
- Novartis Investigative Site - Salzburg
- Novartis Investigative Site - Herlev
- Novartis Investigative Site - Dresden
- Novartis Investigative Site - Mainz
- Novartis Investigative Site - Nijmegen
- Novartis Investigative Site - Barcelona
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Zaragoza
- Novartis Investigative Site - Gothenburg
- Novartis Investigative Site - Lund
- Novartis Investigative Site - Stockholm
- Novartis Investigative Site - Uppsala
- Novartis Investigative Site - London
- Novartis Investigative Site - Manchester
Indiana
- Indiana University Simon Cancer Center SC - Indianapolis
Andalusia
- Novartis Investigative Site - Málaga
Galicia
- Novartis Investigative Site - Santiago de Compostela
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-12-14 |
| Est. Completion | 2018-05-16 |
| Phase | Phase 1 |
What the finished NCT02925104 record still lists
NCT02925104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with cMET Dysegulation Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which INC280 is the first listed.
NCT02925104 lists 17 locations in 4 states (Other, Indiana, Andalusia).
Frequently Asked Questions
What is clinical trial NCT02925104 about?
NCT02925104 is a clinical study titled "A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.". Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food in patients with cMET dysregulated advanced solid tumors.
What is the current status of trial NCT02925104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-12-14. Estimated completion is 2018-05-16.
What conditions does trial NCT02925104 study?
This clinical trial studies the following conditions: cMET Dysegulation Advanced Solid Tumors.
What interventions are being tested in trial NCT02925104?
The interventions under investigation include: INC280 (DRUG).
Who is sponsoring clinical trial NCT02925104?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02925104 being conducted?
This trial has 17 study locations across Indiana, Andalusia, Galicia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02925104's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI